CHD | Connected Health Development – CHD is a Medtech company and eHealth Service Operator operating in Europe

Connected Health Development

CHD (Connected Health Development), founded in 2018, is a Medtech company and eHealth Service Operator operating in Europe.

Discover ↓

Vision & Mission

CHD’s mission is to:

01.

Develop, launch, and operate remote monitoring services for at-risk patients, enabling them to be safely followed from home and in real-life conditions.

02.

Empower healthcare professionals with reliable, high-performance, and easy-to-use remote therapeutic monitoring and medical diagnostic solutions.

By integrating and leveraging the most advanced and proven technologies – including smart textiles, dry sensors, interoperable radio and wireless communication systems, service platforms and applications embedding predictive algorithms into end-to-end solutions – CHD enables healthcare professionals to remotely access precise and meaningful indicators for risk assessment and clinical decision-making.

In doing so, CHD brings connected health to the widest possible audience, improving patients’ quality of life regardless of their chronic condition.

Our connected health and remote monitoring solutions, developed and operated either under our own brand or as white-label services for third parties (pharmaceutical groups, Medtech companies, etc.), are all medical devices certified (CE IIa).

CHD has recently launched a new initiative: MONI2.

01.

Develop, launch, and operate remote monitoring services for at-risk patients, enabling them to be safely followed from home and in real-life conditions.

02.

Empower healthcare professionals with reliable, high-performance, and easy-to-use remote therapeutic monitoring and medical diagnostic solutions.

In doing so, CHD brings connected health to the widest possible audience, improving patients’ quality of life regardless of their chronic condition.

CHD has recently launched a new initiative: MONI2.

15%

of pregnancies

are high-risk

15%

of pregnancies

are high-risk

MONI2: Challenges

Addressing the challenge of high-risk pregnancies:

750,000 pregnancies and births per year in France and 4 million across Europe.

15% are considered high-risk and require close monitoring through hospital visits, inpatient care, or home hospitalization.

The number of maternity units is steadily decreasing, as smaller units are being closed in favor of larger centers (42% of maternity wards in France have closed over the past 25 years).

Current monitoring and diagnostic tools for assessing the health of the fetus and the pregnant woman require the intervention of a healthcare professional, with only a few exceptions suitable for limited home use. However, these alternatives are often uncomfortable, poorly designed for real-life use, and offer limited sensing capabilities — resulting in insufficient health data for effective monitoring and decision-making.

MONI2: Remote monitoring of high-risk pregnancies

CHD is developing MONI2, a maternal-fetal monitoring belt that is comfortable, washable, and designed for real-life use at home. It integrates a wide array of sensors distributed across the pregnant woman’s abdomen, enabling the collection of multiple key physiological parameters for precise monitoring of high-risk pregnancies:

Fetal heart rate

Fetal movements

Maternal heart rate

Maternal contractions

These indicators are remotely accessible to healthcare professionals through secure online services and a web based service platform, as well as via a dedicated mobile app providing simplified access for patients directly from their smartphones.

MONI2: Differentiating factors

MONI2 key competitive advantages:

❶

A higher number of sensors optimally distributed across the maternal abdomen for greater data accuracy.

❷

Fetal ECG rather than Doppler-based heart rate measurement.

❸

A comfortable, fully washable textile device (up to 40 washes).

❹

Usability in real-life conditions.

❺

Relevant predictive health indicators developed through AI-based algorithms.

❻

Two versions: a certified medical version (CE IIa) and a simplified consumer version.

❼

A partnership with a leading global smart-textile manufacturer to develop and industrialize the product, leveraging validated prototypes and proven technologies.

The team

CEO: Laurent Vandebrouck

Entrepreneur specializing in the development, launch, scaling, and operation of digital health solutions and services across Europe and the U.S. Former Managing Director Europe at Qualcomm Life (6 years, USA), CEO of Chronolife (5 years, France), CEO of Restorative NeuroTechnologies (2.5 years, Italy), and CEO of CHD since 2018.

CMO: Prof. Nicolas Sananès

Professor of Obstetrics and Gynecology at the American Hospital of Paris, specialist in prenatal diagnosis and obstetrics. Coordinator of Clinical Guidelines for the French College of Gynecologists and Obstetricians. His research has led to over 100 international publications.

CSO: Dr. Marc Salomon

Cardiologist and intensive care specialist, expert in preventive medicine and digital health entrepreneurship.Medical and Scientific Director for several French digital health startups and organizations. Co-founder of Figaro Santé.fr and active member of multiple healthcare Think Tanks in France. Expert in digital health platforms and the development and certification of new health indicators.

CTO: Fernando Romao

Expert in technical and industrial management of medical devices. Graduate of CentraleSupélec and ENSAM. Former VP Engineering at Chronolife, CTO at Octonion, Head of Development at Archos, and R&D Unit Director at Safran. Expertise in embedded and mobile software, AI, signal processing, and RF systems. Led the certification and industrialization of Chronolife’s connected T-shirt. Author of over 70 patents.

Special Advisor and Scientific Committee: Prof. Vassilis Tsatsaris

Professor of Obstetrics and Gynecology at Maternité Port-Royal (Paris), specialist in high-risk pregnancies. His research has resulted in over 200 scientific and medical publications.